AMRX Q3 2022 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$546M+3.2% YoY

Gross Profit

$194M35.6% margin

Operating Income

$44M8.1% margin

Net Income

-$3M-0.5% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

$94M

Free Cash Flow

$76M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$3.7B

Stockholders' Equity

$297M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$546M	$529M	+3.2%
Gross Profit	$194M	$199M	-2.2%
Operating Income	$44M	$29M	+55.5%
Net Income	-$3M	-$4M	+36.5%

Revenue Segments

Generics Segment

$350M64%

Av K A R E Segment

$106M19%

Amneal Specialty Pharma Segment

$89M16%